As of June 30, 2024, Memphasys Ltd carries a market capitalization of 9.33M, placing it among publicly traded companies globally. Its enterprise value stands at 13.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.33M |
| Enterprise Value | 13.86M |
As of June 30, 2024, Memphasys Ltd has 1.38B shares outstanding.
| Shares Outstanding | 1.38B |
These figures are as of June 30, 2024. The price-to-sales ratio is 259.93, and the price-to-book ratio stands at 1.37.
| PS Ratio | 259.93 |
| PB Ratio | 1.37 |
| P/TBV Ratio | -2.87 |
These figures are as of June 30, 2024. The EV/Sales ratio of 231.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.86M versus a market cap of 9.33M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 231.08 |
As of June 30, 2024, Memphasys Ltd maintains a current ratio of 0.31, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 70.33, indicating elevated leverage, while an interest coverage ratio of -14.19 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.31 |
| Quick Ratio | 0.05 |
| Debt / Equity | 70.33 |
| Debt / EBITDA | -1.06 |
| Interest Coverage | -14.19 |
Over the twelve months ended June 30, 2024, Memphasys Ltd posted a negative return on equity (ROE) of -62.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.78, reflecting losses generated across the asset base. Inventory turnover of 0.40 indicates how many times Memphasys Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -62.46 |
| Return on Assets (ROA) | -32.78 |
| Inventory Turnover | 0.40 |
As of the close on October 22, 2026, Memphasys Ltd's stock has gained approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| 52-Week Price Change | 66.67% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
Over the twelve months ended June 30, 2024, Memphasys Ltd generated 60,000.00 in revenue and converted that into -4.44M in net income, yielding earnings per share of 0.00. EBITDA reached -4.52M, while operating income came in at -5.24M.
| Revenue | 60,000.00 |
| Gross Profit | 1,606.00 |
| Operating Income | -5.24M |
| Pretax Income | -4.44M |
| Net Income | -4.44M |
| EBITDA | -4.52M |
| EBIT | -5.24M |
As of June 30, 2024, Memphasys Ltd holds 277,802.00 in cash and equivalents against 4.81M in total debt, resulting in a net debt position of 4.14M. Total book value stands at 6.84M, with working capital of -3.64M providing operational flexibility.
| Cash & Cash Equivalents | 277,802.00 |
| Total Debt | 4.81M |
| Net Debt | 4.14M |
| Equity (Book Value) | 6.84M |
| Working Capital | -3.64M |
These figures cover the twelve months ended June 30, 2024.
| Capital Expenditures | -638,257.00 |
Over the twelve months ended June 30, 2024, Memphasys Ltd posted a gross margin of 2.68, reflecting its pricing power and cost economics. The operating margin of -8,731.22 and net profit margin of -7,403.37 provide insight into operational efficiency.
| Gross Margin | 2.68 |
| Operating Margin | -8,731.22 |
| Pretax Margin | -7,403.37 |
| Profit Margin | -7,403.37 |
| EBITDA Margin | -7,535.94 |
These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -37.92, meaning Memphasys Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -37.92 |
Memphasys Ltd's most recent stock split took place on October 6, 2025 with a 27:28 split ratio.
| Last Split Date | 10/6/2025 |
| Split Ratio | 27:28 |
As of June 30, 2024, Memphasys Ltd has an Altman Z-Score of -38.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -38.39 |
Already premium?